CHI Advisors LLC
- SEC CIK
- 0001791468
- Latest filing
- Nov 13, 2023
Holdings in Q3 2022
Holdings as of Sep 30, 2022, filed Nov 9, 2022. Long positions only; changes compare share counts with Q2 2022.
- Positions
- 25
- 0 vs. Q2 2022
- Portfolio value
- $371.9M
- +$110.5M (+42.2%) vs. Q2 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| Direxion Shs ETF Tr25460G716 | DAILY S&P BIOTEC | 50,000 | $1.20M | 0.3% | +50,000 | New | – |
| NKTXNkarta, Inc. | COM | 117,599 | $1.55M | 0.4% | −240,414−67.2% | Reduced | History |
| OVIDOvid Therapeutics Inc. | COM | 864,822 | $1.59M | 0.4% | 00.0% | Unchanged | History |
| CRVSCorvus Pharmaceuticals, Inc. | COM | 2,384,402 | $1.95M | 0.5% | +170,218+7.7% | Added | History |
| ONCROncorus, Inc. | COM | 2,367,436 | $2.01M | 0.5% | 00.0% | Unchanged | History |
| RLYBRallybio Corp | COM | 194,297 | $2.81M | 0.8% | +194,297 | New | History |
| Freeline Therapeutics Hldgs35655L107 | SPONSORED ADS | 4,814,419 | $3.37M | 0.9% | −47,900−1.0% | Reduced | – |
| EIGREiger BioPharmaceuticals, Inc. | COM | 455,100 | $3.43M | 0.9% | +265,100+139.5% | Added | History |
| ORTXOrchard Therapeutics plc | ADS | 7,987,396 | $3.99M | 1.1% | +2,679,645+50.5% | Added | History |
| GTHXG1 Therapeutics, Inc. | COM | 323,945 | $4.05M | 1.1% | −443,290−57.8% | Reduced | History |
| IMAImageneBio, Inc. | COM | 1,214,304 | $4.31M | 1.2% | +123,367+11.3% | Added | History |
| DTILPrecision Biosciences Inc | COM | 3,674,820 | $4.78M | 1.3% | +671,069+22.3% | Added | History |
| INZYInozyme Pharma, Inc. | COM | 1,996,277 | $5.35M | 1.4% | −37,525−1.8% | Reduced | History |
| OMGAOmega Therapeutics, Inc. | COMMON STOCK | 1,055,882 | $5.72M | 1.5% | 00.0% | Unchanged | History |
| CMPXCompass Therapeutics, Inc. | COM | 2,829,712 | $6.45M | 1.7% | 00.0% | Unchanged | History |
| KROSKeros Therapeutics, Inc. | COM | 200,229 | $7.53M | 2.0% | +96,800+93.6% | Added | History |
| TSVT2seventy bio, Inc. | COMMON STOCK | 530,223 | $7.71M | 2.1% | −289,449−35.3% | Reduced | History |
| AKUSAkouos, Inc. | COM | 1,288,358 | $8.71M | 2.3% | +452,238+54.1% | Added | History |
| LRMRLarimar Therapeutics, Inc. | COM | 3,415,148 | $10.9M | 2.9% | +1,900,000+125.4% | Added | History |
| KZRKezar Life Sciences, Inc. | COM | 1,762,793 | $15.2M | 4.1% | −78,000−4.2% | Reduced | History |
| Vectivbio Hldg AGH9060V101 | ORD SHS | 4,119,572 | $24.7M | 6.6% | +337,373+8.9% | Added | – |
| RPTXRepare Therapeutics Inc. | COM | 3,069,847 | $37.2M | 10.0% | +423,066+16.0% | Added | History |
| CGEMCullinan Therapeutics, Inc. | COM | 3,243,185 | $41.6M | 11.2% | +195,576+6.4% | Added | History |
| PLRXPliant Therapeutics, Inc. | COM | 3,409,758 | $71.2M | 19.2% | +302,951+9.8% | Added | History |
| RXDXPrometheus Biosciences, Inc. | COM | 1,601,785 | $94.5M | 25.4% | −70,191−4.2% | Reduced | History |
Sold out since Q2 2022 (2)
Positions held at the end of Q2 2022 that are gone from this filing.